Literature DB >> 34350960

The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases.

Nayan Lamba1,2, Ayal A Aizer2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34350960      PMCID： PMC8563309          DOI： 10.1093/neuonc/noab194

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  9 in total

1.  Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.

Authors:  Daniel N Cagney; Brian M Alexander; F Stephen Hodi; Elizabeth I Buchbinder; Patrick A Ott; Ayal A Aizer
Journal:  J Neurooncol       Date:  2016-07-11       Impact factor: 4.130

2.  Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation.

Authors:  Allison M Martin; Daniel N Cagney; Paul J Catalano; Brian M Alexander; Amanda J Redig; Jon D Schoenfeld; Ayal A Aizer
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777

3.  Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Authors:  Michael A Davies; Philippe Saiag; Caroline Robert; Jean-Jacques Grob; Keith T Flaherty; Ana Arance; Vanna Chiarion-Sileni; Luc Thomas; Thierry Lesimple; Laurent Mortier; Stergios J Moschos; David Hogg; Iván Márquez-Rodas; Michele Del Vecchio; Céleste Lebbé; Nicolas Meyer; Ying Zhang; Yingjie Huang; Bijoyesh Mookerjee; Georgina V Long
Journal:  Lancet Oncol       Date:  2017-06-04       Impact factor: 41.316

4.  Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases.

Authors:  Jack M Qian; Allison M Martin; Kate Martin; Lubna Hammoudeh; Paul J Catalano; F Stephen Hodi; Daniel N Cagney; Daphne A Haas-Kogan; Jonathan D Schoenfeld; Ayal A Aizer
Journal:  Cancer       Date:  2020-09-14       Impact factor: 6.860

Review 5.  Chemotherapy delivery issues in central nervous system malignancy: a reality check.

Authors:  Leslie L Muldoon; Carole Soussain; Kristoph Jahnke; Conrad Johanson; Tali Siegal; Quentin R Smith; Walter A Hall; Kullervo Hynynen; Peter D Senter; David M Peereboom; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

6.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Authors:  Georgina V Long; Victoria Atkinson; Serigne Lo; Shahneen Sandhu; Alexander D Guminski; Michael P Brown; James S Wilmott; Jarem Edwards; Maria Gonzalez; Richard A Scolyer; Alexander M Menzies; Grant A McArthur
Journal:  Lancet Oncol       Date:  2018-03-27       Impact factor: 41.316

7.  Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy.

Authors:  Diana D Shi; Omar Arnaout; Wenya L Bi; Elizabeth I Buchbinder; Daniel N Cagney; Megan L Insco; David Liu; Jonathan D Schoenfeld; Ayal A Aizer
Journal:  World Neurosurg       Date:  2020-04-21       Impact factor: 2.104

8.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Authors:  Daniel N Cagney; Allison M Martin; Paul J Catalano; Amanda J Redig; Nancy U Lin; Eudocia Q Lee; Patrick Y Wen; Ian F Dunn; Wenya Linda Bi; Stephanie E Weiss; Daphne A Haas-Kogan; Brian M Alexander; Ayal A Aizer
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

9.  Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).

Authors:  Hussein A Tawbi; Peter A Forsyth; F Stephen Hodi; Christopher D Lao; Stergios J Moschos; Omid Hamid; Michael B Atkins; Karl Lewis; Reena P Thomas; John A Glaspy; Sekwon Jang; Alain P Algazi; Nikhil I Khushalani; Michael A Postow; Anna C Pavlick; Marc S Ernstoff; David A Reardon; Igor Puzanov; Ragini R Kudchadkar; Ahmad A Tarhini; Anne Sumbul; Jasmine I Rizzo; Kim A Margolin
Journal:  Neuro Oncol       Date:  2021-04-21       Impact factor: 12.300
  9 in total
  1 in total

1.  Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases.

Authors:  JiaYu Chang; XuQuan Jing; Ying Hua; KaiXing Geng; RuYue Li; ShuangQing Lu; Hui Zhu; Yan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-23       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.